Microbot Medical® Reports Over 100% Revenue and Customer Growth as Procedure Volume Also Rises in the Second Quarter of 2026
Microbot Medical (Nasdaq: MBOT) reported Q2 2026 revenue and new-customer growth of more than 100% vs Q1 2026, citing the LIBERTY System’s full market release on April 13. The company says procedure volumes rose at prior limited-release sites, expanded U.S. sales territories from 4 to 8 (target 12 by year-end), added a federal-services agreement, and received Israeli marketing clearance.
How this was made
The 30-second read
Why it matters
The company links Q2 growth to full-market adoption, increased procedure volumes at early adopter sites, a federal healthcare agreement, and first marketing clearance outside the U.S., plus capacity expansion via a second manufacturing site.
Market read
Traders may reassess MBOT’s adoption trajectory and commercialization momentum based on the full-market rollout results, territory expansion, federal agreement, and first international clearance.
What to watch
The text doesn’t quantify procedure volumes, revenue dollars, margins, or manufacturing ramp timing; investors may need follow-up on unit economics and whether increased territories translate into sustained utilization.
Background
Microbot Medical’s LIBERTY endovascular robotic system moved from limited to full market release on April 13, 2026, and the company is expanding U.S. sales coverage while pursuing international approvals.
Ticker impact
Microbot Medical reports >100% revenue and new-customer growth in Q2 2026 tied to the LIBERTY System full market release and expanding sales territories.
Likely positive bias for MBOT as investors price in accelerating adoption, broader addressable market, and incremental regulatory progress.
The article provides multiple concrete, company-specific catalysts (full market release adoption, territory expansion, federal agreement, Israel marketing clearance, and a second manufacturing site) but lacks hard financial figures beyond growth claims and no explicit guidance.
Market effects
Could modestly improve sentiment toward endovascular robotics/medical device adoption stories, though impact is likely company-specific given the small-cap scale.
U.S. hospital adoption and federal healthcare coverage expansion may strengthen demand expectations for U.S. medtech procurement cycles.
Israel marketing clearance is an early international foothold that may support broader ex-U.S. commercialization expectations.
Counterpoint
Revenue and customer growth are described as “greater than 100%” without absolute numbers; adoption may still be early and could face reimbursement, utilization, or competitive headwinds.
Key entities
- companyMicrobot Medical Inc.
Developer and distributor of the LIBERTY endovascular robotic system; reports Q2 2026 growth and commercialization milestones.
- partnerLovell Government Services Inc.
Agreement named to serve federal healthcare systems including VHA, MHS, and IHS.
- regulatorIsraeli Ministry of Health (AMAR Division)
Granted marketing clearance for the LIBERTY System, making Israel the first non-U.S. country approval.
